Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O11 | Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade | Shuming Chen, PhD; Abha Soni; Tracee McMiller; John-William Sidhom, MSE; Farah Succaria, MD; Alan Berger; Jody Hooper; Drew M. Pardoll, MD, PhD; Evan Lipson; Janis M. Taube, MD, MSC; Suzanne L. Topalian, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Gene expression; Immune suppression; Immune toxicity; Inflammation; Solid tumors; Tumor microenvironment |
| O12 | B-cells activated by checkpoint blockade immunotherapy and radiation improve overall survival in squamous cell carcinomas | Sangwoo S. Kim, B.A.; Sarek Shen; Sayuri Miyauchi; Philip D. Sanders; Loren K. Mell, MD; J. Silvio Gutkind; Ezra Cohen, MD; Joseph Califano; Andrew B. Sharabi, MD, PhD; | Checkpoint Blockade Therapy | Antibody; B cell; Checkpoint blockade; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O14 | Immune selection for IFN-g signaling mutant cancer cells involves tumor heterogeneity and clonal cooperation | Thomas F. Gajewski, MD, PhD; Shuyin Li, PhD; Jason B. Williams; Emily Higgs; Alexandra Cabanov; Xiaozhong Wang; Haochu Huang; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O15 | Replication stress response defects predict response to immune checkpoint blockade across multiple cancer lineages | Daniel J. McGrail, PhD; Patrick G. Pilie, MD; Truong Nguyen Anh Lam; Hui Dai, MD; Eric Jonasch, MD; Shiaw-Yih Lin, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immunoscore; Systems biology |
| P3 | Predicting patient response to checkpoint blockade therapy using in vitro 3D cultures | Kathryn Appleton, PhD; Ashley K. Elrod; Qi Jin Guo; Dennis Ruder; Tessa DesRochers, PhD; Tessa DesRochers, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P235 | A dense, proliferative myeloid and T cell-rich, immune infiltrate characterizes Immunotherapy-induced skin rash | Cormac Cosgrove, PhD; Cory Kosche; Suyeon Hong; Caroline Le Poole; Jennifer Choi; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Dendritic cell; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell |
| P236 | Nivolumab Related Side Effects Based on Patient-Reported Outcomes: A Multicenter Study from Real-life Setting | Canan Karadas; Zehra Gok Metin, Assoc Prof, PhD, RN; Nur Izgu, PhD, RN; Canan Porucu, MSc, RN; Nuri Karadurmus, Prof. Dr, MD; Sadettin Kilickap, Prof. Dr, MD; Umut Demirci, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Targeted therapy |
| P237 | A case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in HNSCC | Sunil G. Iyer, MD; Nidah Khakoo, MD; Gabriella Aitcheson, MD; Marina Kushnirsky, MD; Cesar A. Perez, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
| P238 | Longitudinal immune and genomic monitoring reveals signatures of response and Immune-related adverse events in cancer patients receiving checkpoint inhibitor therapy | Shaheen Khan, Ph.D; David Gerber; | Checkpoint Blockade Therapy | Antibody; Autoimmunity; Checkpoint blockade; Cytokine; Genetic polymorphism; Immune monitoring; Immune toxicity |
| P239 | Immune checkpoint inhibitor-associated arthritis: a systematic literature review of case series and case reports | Michael D. Tiongson, BA; Nilasha Ghosh, MD; Carolyn Stewart, BA; Karmela K. Chan, MD; Bridget J. Gatto, MLIS; Anne R. Bass, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Inflammation |
| P240 | Quantitative cell-based bioassays to advance immunotherapy programs targeting immune checkpoint receptors | Vanessa Ott, PhD; Jamison J. Grailer, PhD; Jun Wang; Julia Gilden, PhD; Pete Stecha; Denise Garvin; Michael Beck; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie Jey Cheng; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell; Targeted therapy |
| P241 | Single-cell deconvolution identifies T-cell correlates of response to PD-1 blockade treatment in AML | Xingyue An, BS; Jay R Adolacion; Mansour Alfayez; Jairo Matthews; Wilmer Flores; Steven M. Kornblau, MD; Arash Saeedi; Naval Daver, MD; Sreyashi Basu; Navin Varadarajan, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell |
| P242 | Combination of the angiogenesis inhibitor lucitanib with immune checkpoint blockade augments anti-tumor activity in syngeneic models | Rachel Dusek, PhD; Liliane Robillard, PhD; Thomas C. Harding, PhD; Andrew Simmons, PhD; Minh Nguyen; | Checkpoint Blockade Therapy | Angiogenesis; Checkpoint blockade; Gene expression; Targeted therapy; Tumor microenvironment |
| P243 | Modulating the immunogenicity of low-mutation soft tissues sarcomas with epigenetic targeted therapy | himavanth R. gatla, PhD; Maggie Phillips; Brian Ladle; himavanth R. gatla, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Cytokine; Gene expression; Pediatric tumors; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P244 | The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. | Sonia Iyer, PhD; Shuang Zhang; Anniina Farkkila; Sean G. Smith, PhD; David Pepin; Raghav Mohan; Tian Xia; Ferenc Reinhardt; Tony Chavarria; Esmee Hoefsmit; Shailja Pathania; Yunlan Zhou; Kevin Elias; Benjamin Neel; Robert Weinberg, PhD; | Checkpoint Blockade Therapy | Carcinogenesis; Checkpoint blockade; Chemokine; Dendritic cell; Immune contexture; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P245 | Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) – a German radiation oncology survey | Lukas Kaesmann, MD; Chukwuka Eze; Julian Taugner; Olarn Roengvoraphoj; Claus Belka; Farkhad Manapov; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Radiotherapy |
| P246 | Prospective evaluation of outcome and toxicity of durvalumab treatment after chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) patients | Lukas Kaesmann, MD; Julian Taugner; Lukas Kaesmann, MD; Chukwuka Eze; Olarn Roengvoraphoj; Claus Belka; Farkhad Manapov; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Immune toxicity; Radiotherapy |
| P247 | TLR3-targeting Combinatorial Chemokine Modulation Sensitizes “Cold” Tumors for the Therapeutic Effectiveness of Immune Checkpoint Inhibition | Kathleen M. Kokolus, MS, PhD; Natasa Obermajer, PhD; Per H. Basse, MD, PhD; Pawel Kalinski, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P248 | Pembrolizumab plus axitinib (P+A) versus other first-line (1L) systemic therapies for advanced/metastatic clear-cell renal cell carcinoma (ccmRCC) by IMDC Risk Status – a network meta-analysis (NMA) | Ian McGovern, MPH; Rohan Shirali, MS; Andrew Simon, ScM; Yichen Zhong, PhD; Rodolfo Perini, MD; Maria Lorenzi, MSc; Oluwakayode Adejoro, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade |
| P249 | Time-dependent blood transcriptomic perturbations differentially associated with mono and combination checkpoint inhibitor therapy | Darawan Rinchai, PhD; Emily Hinchcliff, MD; Wouter RL. Hendrickx, PhD; Jessica Roelands, Master; Damien Chaussabel; Davide Bedognetti, MD, PhD; Amir A. Jazaeri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Immune monitoring |
| P250 | Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer. | Triparna Sen, PhD | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; Immune monitoring; Targeted therapy |
| P251 | CTX-8371, a novel bispecific targeting both PD-1 and PD-L1, is more potent than combination anti-PD-1 and PD-L1 therapy and provides enhanced protection from tumors in vivo | Diana I. Albu, PhD; Pearl Bakhru; Wilson Guzman, BS; Michael Ophir; Rachel B. McCrory, BS; William Carson; Jason Kong; Beata Bobrowicz; Pia Muyot; Amanda Oliphant; Dalton Markrush; Rachel Rennard; Cheuk Lun Leung; Sara Haserlat; Michael Schmidt; Jose Gonzalo; Bing Gong; Robert Tighe, BS; Diana I. Albu, PhD; Benjamin Wolf; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; T cell |
| P252 | A Retrospective Study to Evaluate Real-World Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Ipilimumab and Nivolumab. | Landon C. Brown, MD; Emily N. Kinsey, MD; Chester Kao, MD; Patrick Healy; Andrew J. Armstrong, MD; Megan A. McNamara, MD; Sundhar Ramalingam, MD; Michael R. Harrision, MD; Daniel J. George, MD; Tian Zhang, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| P253 | Distinct clinical and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro Padron; Yilun Deng, MD, PhD; Harshita B. Gupta, PhD; Aravind Kancharla; Tyler Curiel, MD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; Dendritic cell; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P254 | Requirement of Fc gamma receptor-mediated myeloid-cell activation for effective cancer immunotherapy with an anti-TIGIT antibody | Jin-hwan Han, PhD; Mingmei Cai; Jeffery Grein; Samanthi Perera, PhD; Hongmei Wang; Mike Bigler; Roenna Ueda; Thomas W. Rosahl; Elaine Pinheiro, PhD; Drake LaFace; Wolfgang Seghezzi; Sybil M. Williams, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemokine; Cytokine; Gene expression; Myeloid cells; T cell |
| P255 | Preclinical characterization and efficacy of MG1124, a Novel Immune Checkpoint Blockade targeting CEACAM1 for cancer therapy | Jae-Chul Lee, Master degree; Jae-Chul Lee, Master degree; Minkyu Hur; Hye-Young Park; Mi-Young Oh; Hye-mi Nam; Hye In Yum; HyungSuk Choi; Jaehwan Kim; Byoung Chul Cho, MD.phD; Yangmi Lim; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; NK/NK T cell; T cell; Targeted therapy |
| P256 | A novel bifunctional anti-PD-1 / IL-7 fusion protein potentiates effector function of exhausted T cell and disarms Treg suppressive activity | Aurore Morello, PhD; justine durand; Caroline Mary; virginie Thepenier; Margaux Seite; Géraldine Teppaz; Nicolas Poirier; | Checkpoint Blockade Therapy | Checkpoint blockade; T cell; Targeted therapy |
| P257 | Obesity is associated with diminished anti-PD-1-based immunotherapy response rates in renal cancer | Rachael M. Orlandella, BS; Shannon Boi; Justin T. Gibson, BS; William J. Turbitt; Gal Wald; Lewis Thomas; Katlyn E. Norris; Lakshminarayanan Nandagopal, MD; Peng Li, PhD; Eddy Yang, MD, PhD; Tatiana T. Marquez-Lago, PhD; Lyse A. Norian, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P258 | Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells | Ji-Eun Park, BS.; Bhumsuk Keam, MD, PhD; Ha-ram Park; Soyeon Kim, PhD; Chan-Young Ock, MD, PhD; Miso Kim; Tae Min Kim, MD, PhD; Dong-Wan Kim, MD PhD; Dae Seog Heo; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy |
| P259 | Hydrogel-enabled Intratumoral Co-Delivery of Anti-PD-1 Antibody and Adenosine Deaminase in a Mouse Model of Renal Cell Carcinoma | Ngoc B. Pham, BS; Ketki Velankar, MS; Ngoc B. Pham, BS; Wilson Meng, PhD; Ellen S. Gawalt; Nathan R. Schueller; | Checkpoint Blockade Therapy | Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P260 | Characterization of AB154, a Humanized, Non-depleting α-TIGIT Antibody Undergoing Clinical Evaluation in Subjects with Advanced Solid Tumors | Joanne BL. Tan, PhD; Alejandra Lopez, BSc; Joanne BL. Tan, PhD; Amy Anderson, PhD; Akshata Udyavar, Ph.D; Nell Narasappa, MSC.; Susan J. Lee, PhD; Daniel DiRenzo, PhD; Kristen Zhang, BS; Hema Singh; Sharon Zhao; Kimberline Gerrick; Adam Park; Lisa Seitz, MA; Nigel PC. Walker, PhD; Matthew J. Walters, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune contexture; Immune monitoring; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P261 | Recruitment of CD103+ DCs via tumor stroma-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy | John-Michael Williford, PhD; Jun Ishihara, PhD; Ako Ishihara; Aslan Mansurov, BChen; Tiffany Marchell; Melody Swartz, PhD; Jeffrey Hubbell; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Chemokine; Dendritic cell; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P262 | Schweinfurthins Cause Rapid Induction of Ecto-calreticulin Expression | Ruoheng RZ. Zhang, MBBS; Raymond J. Hohl, MD; Jeffrey D. Neighbors, PhD; Ruoheng RZ. Zhang, MBBS; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune adjuvant |
| P263 | Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancer | Liye Zhou, PhD; Ravindra Uppaluri, MD, PhD; Tenny Mudianto, BS; Xiaojing Ma, PhD; Rachel Riley, BS; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemokine; Immune monitoring; Solid tumors; T cell |
| P264 | Characterization of a human CD137 (4-1BB) receptor binding monoclonal antibody with differential agonist properties that promotes antitumor immunity | Helen Kotanides; Rose Marie Sattler; Maria B. Lebron; Carmine Carpenito, PhD; Juqun Shen; Jingxing Li; David Surguladze; Jaafar N. Haidar; Colleen Burns; Leyi Shen; Ivan Inigo, BS; Anthony L. Pennello; Amelie Forest, MSc; Xinlei Chen; Darin Chin; Andreas Sonyi; Michael Topper; Lauren Boucher; Prachi Sharma; Yiwei Zhang; Douglas Burtrum; Ruslan D. Novosiadly; Dale L. Ludwig; Gregory D. Plowman; Michael D. Kalos; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Costimulation; T cell |
| P265 | Immune checkpoint inhibitors induce response in a dose-dependent manner while their immune related adverse events are dose-independent, a meta-analysis | Osama E. Rahma, MD; Joshua E. Reuss, MD; Anita Giobbie-Hurder, MS; Ghazaleh Razavi, MD; Pooja Mehra, MD; Seema Gupta; Rawad Elias, MD; Samir Khleif, MD; Osama E. Rahma, MD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors |
| P266 | Evaluation of Immunomodulatory Receptor/Ligand Expression on Matched Human Biospecimens | Shawn P. Fahl, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P267 | Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448 | Noemie Wald, PhD; Julia Cuende, PhD; Marjorie Mercier; Florence Nyawouame, MSc; Margreet Brouwer, MSc; Erica Houthuys, PhD; Gregory Driessens, PhD; Veronique Bodo, PhD; Catherine Hoofd; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Coinhibition; Costimulation; Immune contexture; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P268 | IPH5401 anti-human C5aR antibody targets suppressive myeloid cells in the TME | Joanna Fares; Léa Simon; Caroline Soulas; Marion Loivet; Elodie Bonnet; Luciana Batista; Romain Remark, PhD; Cécile Bonnafous; Robert ZERBIB, MSc; Mathieu Bléry; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Granulocyte; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment |
| P269 | IL-15 together with TIGIT blockade reverses PVR-mediated NK cell dysfunction in melanoma. | Joe-Marc JM. Chauvin, PhD; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Cindy Sander; Jiajie Hou; Soldano Ferrone, MD, PhD; Diwakar Davar, MD; John M. Kirkwood, MD; Robert Johnston, PhD; Alan J. Korman, PhD; Mark J. Smyth; Hassane M. Zarour, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; NK/NK T cell; Tumor microenvironment |
| P270 | Expression and clinical significance of the CD47/SIRPα pathway as a candidate immunotherapy target in non-small cell lung cancer (NSCLC) | Shruti Desai, PhD; Franz Villarroel-Espindola; Patricia Gaule, PhD; Adam Ducler; Marisa Peluso, MS; Benjamin Lee, MD PhD; Pamela Holland, PhD; Kurt A. Schalper, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P271 | Anti-SIRPalpha antibodies exert anti-tumor activity in both CD47-dependent and CD47-independent manners | Hongtao Lu, PhD; Xiaofeng Niu, PhD; Qinglin Du, PhD; Jingfeng Yu; Roumei Xing; Yanfen Hu; Jinfeng Zhao; Fengli Wang; Zhihao Wu, PhD; Yangsheng Qiu; Hongtao Lu, PhD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor evasion |
| P272 | SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a | Marisa Peluso, MS; Kshama Doshi, PhD; Caroline M. Armet, BS; Li Zhang; Rachel W. O'Connor, BS; Matthew P. Rausch, PhD; Jonathan A. Hill, PhD; Benjamin Lee, MD PhD; Pamela Holland, PhD; Vito J. Palombella, PhD; Alison M. Paterson, PhD; | Checkpoint Blockade Therapy | Antibody; Monocyte/Macrophage; Myeloid cells; Targeted therapy |
| P273 | Blockade of glyco-immune checkpoint using EAGLE to potentiate anticancer immunity | Li Peng, PhD; Lizhi Cao; Jenny Che; Abhishek Das, PhD; Sujata Nerle; Wayne Gatlin; Robert Leblanc; Zakir Siddiquee; Hui Xu; Karl Normington, PhD, MBA; Weiguo Yao; James Broderick; Li Peng, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P274 | Antibody targeting of tumor associated macrophages in pancreatic cancer and melanoma remodel the tumor microenvironment and revives immune targeting of tumor cells | Dhifaf Sarhan, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P275 | Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade | Julie E. Stein, MD; Evan J. Lipson, MD; Tricia Cottrell, MD, PhD; Patrick Forde, MD; Robert A. Anders, MD, PhD; Ashley Cimino-Mathews; Elizabeth D. Thompson, MD PhD; Mohamad E. Allaf, MD; Mark Yarchoan; Josephine L. Feliciano, MD; Elizabeth M. Jaffee, MD; Drew M. Pardoll, MD, PhD; Suzanne L. Topalian, MD; Janis M. Taube, MD, MSC; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P276 | Efficacy of PD-1/PDL-1 Immune Checkpoint Inhibitors in Elderly Patients with Non-Small-Cell Lung Cancer; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Tumor microenvironment |
| P277 | Utility of PD-L1 Expression in Non-Small-Cell Lung Cancer Patients Treated with PD-1/PDL-1 Immune Checkpoint Inhibitors; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors |
| P278 | PD-1/PDL-1 Immune Checkpoint Inhibitors in Smokers with Non-Small-Cell Lung Cancer; A Subgroup Meta-Analysis of Randomized Controlled Trials | Faisal S. Ali; Bibek Pannu; Maryam R. Hussain; Arafat Farooqui; Taha Alrifai; Phyo T. Myint; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Carcinogenesis; Checkpoint blockade; Chemotherapy; Tumor microenvironment |
| P279 | PDL-1 is highly expressed in ovarian germ cell tumor and associated with cancer stem cells population expressing CD44 | Kholoud Alwosaibai, PhD; Salmah Alamri; Miral Mashhour; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P280 | Impact of tumor mutational burden on overall survival in patients with non-small cell lung cancer treated with immunotherapy | Mark Awad, MD PhD; Navin R. Mahadevan; Andrew Polio; Natalie Vokes; Elizabeth J. Aguilar; Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Gonzalo Recondo, MD; Giulia C. Leonardi; Anika Adeni; Pasi A. Janne, MD PhD; Eliezer Van Allen, MD; Adem Albayrak, M.S.; Renato Umeton; Lynette M. Sholl; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P281 | Durable response after immunotherapy discontinuation: a multicenter real-life experience | Maria Bassanelli, MD, PhD; Diana Giannarelli, MD; Marco Russano; Fabiana Letizia Cecere; Maria Rita Migliorino; Silvana Giacinti; Viola Barucca; Emilio Bria; Enzo Maria Ruggeri; Fabio Calabrò; Alain Gelibter; Daniele Santini; Anna Ceribelli; | Checkpoint Blockade Therapy | Immune toxicity; Solid tumors |
| P282 | Tumor-targeted T-cell Activation via an Investigational PD-L1 x CD137 Bispecific Molecule | Alexey Berezhnoy, PhD; Ling Huang; Daorong Liu; Jennifer DiChiara; Jonathan Li, PhD; Douglas Smith, PhD; Jill R. Rillema, BS; Valentina Ciccarone, PhD; James K. Tamura, PhD; Ralph F. Alderson, PhD; Gundo Diedrich; Ezio Bonvini, PhD; Paul Moore, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P283 | Generation and Characterization of a PD-1 Resistant Mouse Tumor Model | Marie Bernardo, PhD; Tatiana Tolstykh; Yu-An Zhang; Dinesh Bangari; Hui Cao, PhD; Joon Sang Lee, PhD; Natalia Malkova; Jack Pollard, PhD; Fangxian Sun; Dmitri Wiederschain; Timothy Wagenaar; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Tumor microenvironment |
| P284 | Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice | Tiina E. Kähkönen; Mari I. Suominen; Jenni HE. Mäki-Jouppila; Emrah Yatkin; Philip Dube; Azusa Tanaka; Jussi M. Halleen; Jenni Bernoulli, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P285 | Integrated Molecular Characterization of primary resistance mechanisms to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Carcinoma (a-NSCLC) | Benjamin Besse, MD PhD; Caroline Fraslon, PhD; Hui Cao, PhD; Joon Sang Lee, PhD; Stephanie Malyszka, MS; Marielle Chiron, PhD; Anne Caron, PhD; Souâd Naimi, PhD; Laura Mezquita, MD; David Planchard, MD, PhD; Jean-Yves Scoazec, MD; Ludovic Lacroix, PharmD; Etienne Rouleau, MD; Naima Imam-Sghiouar, PhD; Aurélien Marabelle, MD PhD; Eric Angevin, MD; Christophe Massard, MD; Jack Pollard, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Immune contexture; Myeloid cells; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P286 | In vivo genetic screens in PD-1 resistant mouse models identified modulators of anti-PD1 response with relevance to pembrolizumab-treated human metastatic melanoma | Aurélie Docquier, PhD; Cécile Déjou; Gilles Alberici; Armand Bensussan, PhD; Jeremy Bastid; Nathalie Bonnefoy, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune suppression |
| P287 | A novel bispecific checkpoint inhibitor antibody to preferentially block PD-1 and LAG-3 on dysfunctional TILs whilst sparing Treg activation | Laura Codarri Deak; Patrick A. Weber, Mr.; Stefan Seeber, Dr.; Mario Perro, Dr.; Xavier Miot, Mr.; Heidi Poulet, Mrs.; Iryna Dekhtiarenko, Dr.; Matthias Füth; Henry Kao, Dr.; Christine McIntyre, Dr.; Francesca Michielin, Dr.; Christian Klein, Dr rer nat; Pablo Umana, PhD; Lin-Chi Chen, Dr.; Christoph Markert, Dr.; Merlind Mücke, Dr.; | Checkpoint Blockade Therapy | Checkpoint blockade; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P288 | CCR5+CTLA4+ Treg cell subset characterizes renal tumors (RCC) immunosuppressed by PD1 blockade | Agathe Dubuisson; Charles Bayard; Sebastien Lofek; Nicolas Voisin; Séverine Mouraud; Delphine Bredel; Sandrine Susini; Mathieu Rouanne, MD; Hervé Beaumert; Bastien Parier; Aurélien Marabelle, MD PhD; Laurence Zitvogel, MD, PhD; Mélodie Bonvalet; | Checkpoint Blockade Therapy | Biomarkers; Chemokine; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P289 | Macrophages modulate patient response to immune checkpoint inhibition in a novel lung tumour explant model | Lauren Evans, BSc, MSc; Kate Milward, DPhil; Richard Attanoos, BSc, MB BS, FRCPath; Aled Clayton, PhD; Rachel Errington, PhD; Zsuzsanna Tabi, PhD; | Checkpoint Blockade Therapy | Antigen presenting cells; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment |
| P290 | Interferon Gamma Production by Regulatory T cells is Necessary for Response to Cancer Immunotherapy | Angela M. Gocher, PhD; Dario A. Vignali, PhD; Creg Workman, PhD; Sanah Handu; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P291 | Driving T cell dysfunction in vitro for rational immunotherapy design | Matthew Hancock; Cailin CJ. Joyce, PhD; Thomas Horn; Simarjot Pabla; Benjamin Duckless; Andrew Basinski; Dhan Chand, PhD; Jeremy D. Waight, PhD; Mariana Manrique, PhD; Nicholas S. Wilson; Alex Duncan, PhD; Jennifer S. Buell, PhD; David Savitsky, PhD; Lukasz Swiech; John C. Castle, PhD | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Systems biology; T cell; Tumor evasion; Tumor microenvironment |
| P292 | Tissue site of tumor growth dictates anti-tumor immunity and response to checkpoint blockade | Brendan L. Horton, PhD; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Tumor microenvironment |
| P293 | Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas | Bryan Iorgulescu, MD; Mehdi Touat; Yvonne Li; Liam Spurr; Gareth Grant; William Pisano; Mary Jane Lim-Fat; Eudocia Lee; Lakshmi Nayak; E Chiocca; Raymond Huang; Andrew Cherniack; Patrick Wen; Ahmed Idbaih; Franck Bielle; David A. Reardon, MD; Keith Ligon; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study |
| P294 | Long survival associated with receipt of anti-CTLA-4 in patients with metastatic melanoma from acral lentiginous, mucosal and uveal primary tumors | Nicholas D. Klemen, MD; Melinda Wang, BS; Kelly Olino, MD; James Clune, MD; Stephan Ariyan, MD; Charles Cha, MD; Sarah A. Weiss, MD; Harriet Kluger, MD; Mario Sznol, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Neoantigens; Surgery; Tumor antigens; Tumor evasion |
| P295 | The impact of metastatic sites on checkpoint inhibitor outcomes in patients with cutaneous and unknown primary melanoma | Penina P. Krieger, MPhil; Francisco Sanchez-Vega; Nikolaus Schultz; Alexander N. Shoushtari, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P296 | BMI, irAE and gene expression signatures predict resistance and survival to immune-checkpoint inhibition in renal cell carcinoma | Brian W. Labadie, MD; Ping Liu, PhD; Riyue Bao, PhD; Michael Crist, MD; Ricardo Fernandes, MD; Laura Ferreira Freire; Scott Graupner; Andrew Poklepovic, MD; Ignacio Duran; Saman Maleki Vareki; Arjun V. Balar, MD; Jason J. Luke, MD, FACP; | Checkpoint Blockade Therapy | Angiogenesis; Biomarkers; Checkpoint blockade; Solid tumors; Systems biology; Targeted therapy; Tumor microenvironment |
| P297 | A semi-mechanistic platform model to capture individual animal responses to checkpoint inhibitors in a syngeneic mouse model | Lin Lin, PhD; Alison Betts; Carissa L. Young; Wendy Qiao; Jatin Narula; Peter O’Brien; Derek Bartlett; Andrea Hooper; Jason Williams; John Burke; Joshua Apgar; Lore Gruenbaum, PhD; Fei Hua, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P298 | PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma | Xiande Liu, Ph.D; Wen Kong; Christine B. Peterson; Daniel J. McGrail; Anh Hoang; Xuesong Zhang; Truong Lam; Patrick G. Pilie, MD; Haifeng Zhu, PhD; Kathryn E. Beckermann; Scott M. Haake; Sevinj Isgandrova; Margarita Martinez-Moczygemba; Nidhi Sahni; W. Kimryn Rathmell; Eric Jonasch, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P299 | Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity | Chang Liu, PhD; Ashwin Somasundaram, MD; Sasikanth Manne; Angela M. Gocher, PhD; Andrea L. Szymczak-workman; Kate M. Vignali; Daniel P. Normolle, PhD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P300 | Real World data analysis related to metastatic melanoma patients treated with immunotherapy from 2012 to 2018 at Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale” of Napoli, Italy | Gabriele Madonna; Mariaelena Capone, MD; Marilena Tuffanelli; Marcello Curvietto, PhD; Miriam Paone, PhD; Assunta Esposito, PhD; Antonio Sorrentino; Marco Palla; Luigi Scarpato; Domenico Mallardo, MD; Ester Simeone, MD; Antonio M. Grimaldi, MD; Kristina Viktorsson; Lisa Villabona; Rolf Lewensohn; Giuseppe V. Masucci, MD, PhD; Paolo Antonio A. Ascierto, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
| P301 | Expression of tumor matrix metalloproteases ADAM10 and ADAM17 correlates with low PD-L1 protein-to-mRNA ratio in multiple tumors, predicting poor outcomes. | Jacob Orme, MD PhD; Aaron Mansfield, MD; Jacob Orme, MD PhD; Jacob Orme, MD PhD; Roxana Dronca, MD; Haidong Dong, MD, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Proteomics; Tumor microenvironment |
| P302 | A Reversible T Cell Exhaustion-Like In Vitro Assay to Screen Candidate Drugs | Wushouer Ouerkaxi; Eden Kleiman; Pirouz M. Daftarian; Wushouer Ouerkaxi; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Autoimmunity; Checkpoint blockade; Immune monitoring; Immune tolerance; T cell; Tumor evasion |
| P303 | PD-1 checkpoint blockade in advanced melanoma patients: Neutrophils, NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates | Yago Pico de Coaña; Maria Wolodarski, MD; Irene van der Haar Àvila; Takahiro Nakajima; Stamatina Rentouli; Andreas Lundqvist, PhD; Giuseppe V. Masucci, MD, PhD; Johan Hansson; Rolf Kiessling, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; MDSC; NK/NK T cell |
| P304 | DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer | Biagio Ricciuti, MD; Gonzalo Recondo, MD; Renato Umeton; Giuseppe Lamberti, MD; Mizuki Nishino; Lynette M. Sholl; Michael Cheng; Mark Awad, MD PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P305 | Response to Pembrolizumab and tumor microenvironment composition is associated with IL8 expression in a head and neck squamous-cell carcinoma cohort | Arun Khattri, PhD; Jason W. Reeves; SuFey Ong; Riyue Bao, PhD; Arya Bahrami, PhD; Yi-Hung Carol Tan, PhD; Andrew M. White, BSc; Michael P. Bailey; Heather A. Brauer, PhD; Sarah Warren, PhD; Joseph M. Beechem, PhD; Tanguy Seiwert, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P306 | Innate immune cells play a role in therapy resistance to anti-PD1 in Hu-mice melanoma model. | Raj Somasundaram, PhD; Meenhard Herlyn, DVM PhD; Raj Somasundaram, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Tumor microenvironment |
| P307 | The impact of Metformin (M) on the response rates of checkpoint Inhibitors (CPI) | Philip A. Haddad, MD, MPH; David Sommerhalder, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P308 | The impact of obesity on the response rates of checkpoint Inhibitor (CPI) cancer immunotherapy | Philip A. Haddad, MD, MPH; David Sommerhalder, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment |
| P309 | Older age predicts better outcome to neoadjuvant immune checkpoint blockade in metastatic melanoma | Rohit Thakur; Rohit Thakur; Stephen Douglass, PhD; Beth Helmink, MD PhD; Rodabe N. Amaria, MD; Hussein A. Tawbi, MD, PhD; Jennifer McQuade; Eliza Rozeman; Elizabeth Burton; Sangeetha M. Reddy, MD, MSci; John Wherry; Christian Blank, MD PhD; Georgina Long; Jeffrey E. Gershenwald, MD; Michael Davies, MD, PhD; Michael T. Tetzlaff, MD PhD; Ashani Weeraratna; Jennifer A. Wargo, MD, MMSc; | Checkpoint Blockade Therapy | Antigen presenting cells; Checkpoint blockade; Tumor antigens; Tumor evasion; Tumor microenvironment |
| P310 | Optimal priming prevents the induction of dysfunctional CD8 T-cells in subprimed conditions, reversing resistance to anti-PD-1. | Vivek Verma, PhD; Rahul Nandre, PhD; Jose Lopez; Seema Gupta, PhD; Samir N. Khleif, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell; Tumor microenvironment; Vaccine |
| P311 | Dual antagonism of prostaglandin receptors EP2 and EP4 by TPST-1495 suppresses tumor growth and stimulates anti-tumor immunity | Chan C. Whiting, PhD; Kim Fischer, PhD; Bryan Laffitte, PhD; Lisa Rahbaek, PhD; Nick Stock, PhD; Davorka Messmer, PhD; Austin Chen, PhD; Traci Olafson; Natalie Nguyen; Amanda Enstrom, PhD; Derek Metzger; Brian Francica; Dingzhi Wang, PhD; Raymond Dubois, PhD, MD; Ginna G. Laport, MD; Peppi Prasit, PhD; Thomas W. Dubensky, Jr., PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P312 | Ipilimumab treatment immunophenotypic changes are associated with progression of disease with sequential nivolumab therapy in metastatic melanoma | David M. Woods, PhD; Andressa Sodre Laino, PhD; Aidan Winters; Jason Alexandre; Jeffrey S. Weber, MD, PhD; Pratip Chattopadhyay; David M. Woods, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; T cell |
| P313 | Single-cell secretome assessment of metastatic melanoma patient peripheral T-cells reveals a pharmacokinetic signature of patient response to nivolumab therapy. | David M. Woods, PhD; Andressa Sodre de Castro Laino; Daniel Freeman; Jeffrey S. Weber, MD, PhD; Pratip Chattopadhyay; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Cytokine; T cell |
| P314 | Alterations of DNA damage response signaling in the development of antibody-dependent cellular cytotoxicity (ADCC) resistance | Yongwei Zhang; Louis M. Weiner, MD; Yongwei ZHANG; Dalal Aldeghaither; David Zahavi, MS, BS; | Checkpoint Blockade Therapy | Adoptive immunotherapy; Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; Neoantigens; NK/NK T cell; Solid tumors; Targeted therapy |
| P315 | The expression of programmed death ligand 2 (PD-L2) in immunosuppressive tumor microenvironment of non-small cell lung cancer (NSCLC) and its potential association with immunotherapy | Qu Zhang, PhD; Stefan Bentink; Vinay Pawar; Farzad Sekhavati, PhD; Keith E. Steele, DVM, PhD; Jason Hipp; Song Wu, PhD; | Checkpoint Blockade Therapy | Biomarkers; Clinical trial; Gene expression; Immune suppression; T cell; Tumor microenvironment |
| P316 | MG1131, a novel TIGIT-targeted monoclonal antibody, induces T cell activation and anti-tumor immune response and suppresses Treg cell activity | Hyemi Nam, MS; Hye-Young Park; Eun Jung Song; Eunhee Lee; Hye In Yum; Munkyung Kim; Jeewon Lee, Ph D; So Jung Lim; Okjae Lim; Yangmi Lim; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| P317 | Utilization of Second-Line Immuno-Oncology Agents and Associated Health Outcomes Among United States Veterans with Advanced Non-Small Cell Lung Cancer | Mina A. Allo, PharmD, MPH; Lin Gu, MS; Vishal Vashistha, MD; Ashlyn Press, MPH; Michael J. Kelley, MD; Christina Williams, PHD, MPH; Mina A. Allo, PharmD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Epidemiology |
| P318 | Large-scale evaluation of concordance of genomic scores in whole exome sequencing and Foundation Medicine comprehensive genomic platform across cancer types | Deepti Aurora-Garg; Andrew Albright, PhD; Ping Qiu, PhD; Yongjin Li; Xiaoqiao Liu; David Fabrizio, PhD; Lixin Lang; Jared Lunceford, PhD; Razvan Cristescu, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors |
| P319 | Changes in Fatigue Severity, Health Related, and Dermatology Related Quality of Life in Melanoma Patients Receiving Nivolumab: Preliminary Results of a Prospective Study from Real-life Experience | Canan Karadas; Nur Izgu, PhD, RN; Zehra Gok Metin, Assoc Prof, PhD, RN; Canan Porucu, MSc, RN; Nuri Karadurmus, Prof. Dr, MD; Sadettin Kilickap, Prof. Dr, MD; Umut Demirci, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Targeted therapy |
| P320 | Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors | Anya Avrutskaya; Fabienne Sonego; Jacob Hauser; Emily O’Koren; Robin Ball; Gaëlle Martin; Julie Chaix; Thi Bui; Ian Belle; Elizabeth Reap; Patrick Fadden, PhD; Chassidy Hall; Kader Thiam; Paula Miliani de Marval; | Checkpoint Blockade Therapy | Checkpoint blockade; Tumor infiltrating lymphocytes (TILs) |
| P321 | Real-world clinical outcomes among patients with advanced non-small cell lung cancer who initiated first-line regimens | Eric Nadler, MD; Eric Nadler, MD; Bhakti Arondekar, PhD; Kathleen M. Aguilar; Jie Zhou; Jane Chang; Xinke Zhang; Vivek Pawar; | Checkpoint blockade therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| P322 | COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo | Maya Kotturi, BS, PhD; Eran Ophir, PhD; Eran Ophir, PhD; Sarah Whelan, PhD; Spencer Liang; Kathryn Logronio, BS PhD; Kyle Hansen, BS; Zoya Alteber, PhD; Mark White, BS, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P323 | IPH5301, a CD73 blocking antibody targeting the adenosine immunosuppressive pathway for cancer immunotherapy. | Ivan Perrot; Caroline Denis, PhD; Marc Giraudon-Paoli; Severine Augier; Rachel Courtois; Diana Jecko; Violette Breso; Thomas Arnoux; Nicolas Gourdin, PhD; Romain Remark, PhD; Cecile Bonnafous; Ariane Morel, PhD; Eric Vivier; Yannis Morel, PhD; Pascale Andre; Carine Paturel, PhD; | Checkpoint Blockade Therapy | Antibody; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P850 | Metabolically reprogram MDSCs by targeting Pim kinases to overcome resistance to PD-1 blockade immunotherapy | Gang Xin; Yao Chen; Paytsar Topchyan; Aimin Jiang, PhD; Yiliang Chen; Roy Silverstein; Weiguo Cui; Gang Xin; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; Solid tumors; Tumor microenvironment |
Late-Breaking | ||||
| P854 | Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets | Nils-Petter Rudqvist, PhD , Roberta Zappasodi, PhD, Daniel Wells, PhD, Vésteinn Thorsson, PhD, Alexandria Cogdill, MEng, Anne Monette, PhD, Yana Najjar, MD, Randy Sweis, MD, Erik Wennerberg, PhD, Praveen Bommareddy, PhD0, Cara Haymaker, PhD, Uqba Khan, MD, Heather McGee, MD, PhD, Wungki Park, MD, Houssein Abdul Sater, MD, Christine Spencer, PhD, Nicholas Tschernia, MD, Maria Ascierto, PhD, Valentin Barsan, MD, Vinita Popat, PhD, Sara Valpione, MD, PhD, Benjamin Vincent, MD | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Systems biology; Tumor microenvironment |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
